ClinicalTrials.gg
Not yet recruitingNCT07663123HARVESTUpdated Sep 15, 2026

Health Assessment of Low Glycaemic Index - High Protein Rice to Enhance Glycemic Control Through Nutrition

An interventional study of Functional rice variaties in Prediabetes / Type 2 Diabetes, sponsored by Institute for Human Development and Potential (IHDP), Singapore. Not yet recruiting. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Institute for Human Development and Potential (IHDP), Singapore · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Study summary

Type 2 Diabetes (T2D) represents a critical public health challenge in Singapore, with prevalence projected to reach one million residents by 2050. This epidemic is largely driven by a distinct "Asian phenotype" characterized by reduced insulin secretion capacity even at lower BMIs and a diet heavily centered on high-glycemic index (GI) white rice. While brown rice offers superior nutritional benefits, its global and local adoption remains low due to entrenched cultural preferences, shorter shelf life, and sensory barriers.

While the link between high-GI carbohydrates and metabolic dysfunction is well-documented, there is limited clinical evidence on the effects of "functional" white rice varieties specifically those engineered to combine low GI properties with significantly enhanced protein content on long-term glycemic control, metabolic and gut microbiome health in Asian populations. The importance of this research lies in its evaluation of a culturally seamless substitution strategy. By replacing conventional white rice with Low-GI (LGI) and High-Protein Low-GI (LGI-HP) varieties, the HARVEST study addresses the metabolic burden of prediabetes without requiring major behavioral shifts. The findings will provide vital mechanistic insights into glucose regulation, insulin sensitivity, and microbial dysbiosis, to provide the evidence based for nutritional strategies for T2D prevention and management.

Read the detailed description
  1. To evaluate the efficacy of a 16-week intervention with functional rice varieties (LGI, LGI-HP) on chronic glycaemic management in Singaporean adults with prediabetes. It is hypothesized that dietary replacement of habitual rice with functional varieties can significantly improve metabolic health compared to the high-GI (HGI) control group
  2. To compare the postprandial glucose and insulin responses of LGI, LGI-HP and HGI rice under standardized acute meal testing using continuous glucose monitoring. It is hypothesized that postprandial glucose excursions and glycemic variability will be significantly attenuatated in the functional rice groups compared to the HGI group
  3. To characterise longitudinal shifts in gut microbiota composition and identify mechanistic correlations between microbial changes and glucose metabolism. It is hypothesized that long term consumption of functional rice will promote beneficial shift in the gut microbiome which are associated with improved glucose homeostasis.
02

Conditions studied

  • Prediabetes / Type 2 Diabetes

Keywords

  • Prediabetes
  • Type 2 Diabetes prevention
  • Nutrition
  • Metabolic dysfunction
03

In context

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

This study's planned enrollment of 225 is above the median of 62 across 763 interventional studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

Institute for Human Development and Potential (IHDP), Singapore is the lead sponsor of 24 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, aged 40 to 65 years old
  2. Chinese, Malay or Indian
  3. between 23.0 - 32.0 kg/m2
  4. Prediabetes profile as per fasting plasma glucose (≤ 6.9 mmol/L) and level (5.7% - 6.4%)
  5. Habitually consuming about 3 to 5 servings of polished white rice per day
  6. No known food allergies and intolerance to food provided as part of study procedures
  7. Proficient in English language
  8. Willing to comply to study procedures and provide written consent

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with Type 1 or 2 diabetes mellitus/ OGTT failure during screening visit
  2. History or current diagnosis of cardiovascular, endocrine, gastrointestinal, haematological, hepatitis ( and C), cancers (except basal cell carcinoma), chronic kidney disease or other medical conditions which may affect study outcomes, as assessed by study team
  3. Having chronic medication (eg: metformin, oral etc), and/or supplements that may influence glycaemic management and other study outcomes, as assessed by study team
  4. History of bariatric surgery
  5. Significant weight change (± 5 % body weight) during the last 3 months
  6. Women who are pregnant, breastfeeding or planning pregnancy
  7. Drug abuse within the last 5 years
  8. Excessive alcohol consumption > 2 servings per day
  9. Smoking in the last 1 year
  10. Following any special diet(s) which may interfere with study outcomes (eg: Ketogenic diet, intermittent fasting, calorie-deficit)
  11. Major change in physical activity and/or dietary habits in the last 3 months
  12. Use of oral antibiotics in the last 3 months
  13. Participation in other intervention studies, which may affect study outcomes as assessed by study team
  14. Staff of IHDP and SIFBI in A*STAR
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
225 participants (estimated)

Study arms

  • Experimental
    High glycaemic index rice (HGI)

    Participants will replace their habitual rice consumption with 4 servings (equivalent to approximately 2 bowls or \~400 g of cooked rice) per day of HGI rice while keeping other dietary components consistent.

    Dietary Supplement: Functional rice variaties

  • Experimental
    Low glycaemic index rice (LGI)

    Participants will replace their habitual rice consumption with 4 servings (equivalent to approximately 2 bowls or \~400 g of cooked rice) per day of LGI rice while keeping other dietary components consistent.

    Dietary Supplement: Functional rice variaties

  • Experimental
    Low glycaemic index high protein rice (LGI-HP)

    Participants will replace their habitual rice consumption with 4 servings (equivalent to approximately 2 bowls or \~400 g of cooked rice) per day of LGI-HP rice while keeping other dietary components consistent.

    Dietary Supplement: Functional rice variaties

Interventions

  • Dietary supplementFunctional rice variaties

    Single-blinded, 16 week parallel randomized controlled trial (RCT) involving 225 participants with prediabetes. Participants are randomized into one of three arms to consume either high glycaemic index rice (HGI), low glycaemic index rice (LGI), or low glycaemic index high protein rice (LGI-HP). In each arm (n = 75), participants will replace their habitual rice consumption with 4 servings (equivalent to approximately 2 bowls or \~400 g of cooked rice) per day of the assigned rice group while keeping other dietary components consistent.

06

What researchers measure

Primary outcomes

  1. Change in Haemoglobin A1c (HbA1c) levels

    To evaluate the efficacy of a 16-week intervention with functional rice varieties on chronic glycaemic management in Singaporean adults with prediabetes, as measured by change in Haemoglobin A1c (HbA1c) levels.

    Time frame: 16 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Camps SG, Kaur B, Lim J, Loo YT, Pang E, Ng T, Henry CJ. Improved Glycemic Control and Variability: Application of Healthy Ingredients in Asian Staples. Nutrients. 2021 Sep 3;13(9):3102. doi: 10.3390/nu13093102. PubMed 34578981 ↗
  • Kaur B, Koh M, Ponnalagu S, Henry CJ. Postprandial blood glucose response: does the glycaemic index (GI) value matter even in the low GI range? Nutr Diabetes. 2020 May 1;10(1):15. doi: 10.1038/s41387-020-0118-5. PubMed 32358482 ↗
  • Toh DWK, Fu AS, Mehta KA, Lam NYL, Haldar S, Henry CJ. Plant-Based Meat Analogs and Their Effects on Cardiometabolic Health: An 8-Week Randomized Controlled Trial Comparing Plant-Based Meat Analogs With Their Corresponding Animal-Based Foods. Am J Clin Nutr. 2024 Jun;119(6):1405-1416. doi: 10.1016/j.ajcnut.2024.04.006. Epub 2024 Apr 8. PubMed 38599522 ↗
  • Toh DWK, Ponnalagu S, Camps SG, Lim J, Koh MXN, Henry CJ. Higher adiposity predicts greater intra-individual inconsistencies in postprandial glycemic measurements-an analysis of three randomized controlled trials in Asian populations. Eur J Clin Nutr. 2024 Sep;78(9):788-795. doi: 10.1038/s41430-024-01457-1. Epub 2024 Jun 12. PubMed 38866975 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2029, 30 months later.

Of 379 non-industry interventional studies with no phase under Prediabetic State, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 30 months is above that.

Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jun 23, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Apr 30, 2029
CompletionEst.
Apr 30, 2029
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07663123
Lead sponsor
Institute for Human Development and Potential (IHDP), Singapore
Collaborators
Novo Nordisk A/S
Responsible party
Johan Eriksson (Executive Director, Institute for Human Development and Potential (IHDP), Singapore) — Principal investigator
First posted
Jun 23, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Apr 30, 2029 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Sep 15, 2026

Study contacts

Johan G. Eriksson, MD
Contact
obgjge@nus.edu.sg
+65 6407 0100
Johan G. Eriksson, MD
principal investigator · A*STAR Institute for Human Development and Potential (A*STAR IHDP)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion